TY - JOUR
T1 - Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer
AU - Yong Chan Ahn, Chan Ahn
AU - Park, K.
AU - Dae Yong Kim, Yong Kim
AU - Kwan Min Kim, Min Kim
AU - Kim, J.
AU - Young Mog Shim, Mog Shim
AU - Kyung Soo Lee, Soo Lee
AU - Han, J.
AU - Ho Joong Kim, Joong Kim
AU - O Jung Kwon, Jung Kwon
AU - Do Hoon Lim, Hoon Lim
AU - Young Joo Noh, Joo Noh
AU - Jeong Eun Lee, Eun Lee
AU - Seung Jae Huh, Jae Huh
PY - 2001
Y1 - 2001
N2 - Thirty-one patients with stage IIIA non-small cell lung cancer (NSCLC) were treated with preoperative concurrent chemoradiotherapy (CCRT) followed by surgery. The treatment protocol could not be completed in eight patients. The acute hematologic toxicities of grade III or IV occurred in 48.4% (15/31) after the first chemotherapy cycle, and in 39.1% (9/23) after the second cycle. The most common non-hematologic toxicity was radiation esophagitis. Surgery was attempted in 23 patients and successful in 22 patients (resection rate = 71.0%). Pathologic complete response and down-staging were achieved in 13.6% (3/22) and 68.2% (15/22). The median survival period, 2-year overall survival, local control and disease-free survival rates of all 31 patients and of 22 patients who underwent surgery were 19 months, 37.2%, 49.1%, 35.5%, and 19 months, 43.2%, 51.8%, 25.6%, respectively. On the basis of our observations, preoperative CCRT followed by surgery for stage IIIA NSCLC has resulted in outcomes comparable with those in previous reports.
AB - Thirty-one patients with stage IIIA non-small cell lung cancer (NSCLC) were treated with preoperative concurrent chemoradiotherapy (CCRT) followed by surgery. The treatment protocol could not be completed in eight patients. The acute hematologic toxicities of grade III or IV occurred in 48.4% (15/31) after the first chemotherapy cycle, and in 39.1% (9/23) after the second cycle. The most common non-hematologic toxicity was radiation esophagitis. Surgery was attempted in 23 patients and successful in 22 patients (resection rate = 71.0%). Pathologic complete response and down-staging were achieved in 13.6% (3/22) and 68.2% (15/22). The median survival period, 2-year overall survival, local control and disease-free survival rates of all 31 patients and of 22 patients who underwent surgery were 19 months, 37.2%, 49.1%, 35.5%, and 19 months, 43.2%, 51.8%, 25.6%, respectively. On the basis of our observations, preoperative CCRT followed by surgery for stage IIIA NSCLC has resulted in outcomes comparable with those in previous reports.
UR - https://www.scopus.com/pages/publications/0034799775
U2 - 10.1080/028418601750444123
DO - 10.1080/028418601750444123
M3 - Article
C2 - 11669330
AN - SCOPUS:0034799775
SN - 0284-186X
VL - 40
SP - 588
EP - 592
JO - Acta Oncologica
JF - Acta Oncologica
IS - 5
ER -
